Feb
28
2017
On demand

Advances in viral vector technology: Anc-AAV & evolutionary guided vector design

Gene therapy is a potent modality with demonstrated ability to intervene in diseases of unmet medical need. Its safety and efficacy is often governed by the vector system used. Adeno-associated viral vectors (AAV) have shown great promise for sustained expression of a therapeutic gene in vivo. Obstacles remain however for gene therapy to broaden its impact beyond niche indications; currently clinically considered AAVs are repurposed naturally occurring viral entities that bring along limitations imposed by its viral biology. For example, AAVs is endemic in humans which results in a large proportion of patients to harbor memory responses to AAV antigens, preventing them to benefit from a future AAV gene therapy. Other constraints include AAV’s limited genetic cargo capacity, poor targeting of tissue targets (e.g. kidney, cochlea), and a desire to increase transduction specificity of an inherently promiscuous virus. This webinar provides insight into:

  • The novel discovery efforts aimed at building synthetic AAV-based gene transfer vehicles that diverge sufficiently from their natural peers
  • The challenges in retaining the superior features that have justified AAV's current clinical use
  • Their work in deconstructing the putative viral evolutionary lineage of most of the commonly used AAVs using Ancestral Sequence Reconstruction
  • Subsequent efforts that have led on the one hand to a set of uniquely distinct AAVs with potent transduction of therapeutically relevant tissues (including liver, retina, muscle, and cochlea). On the other hand, they actively exploit these novel reagents to deepen our structure-function understanding toward the development of improved clinical gene transfer reagents




Dr Luk H. Vandenberghe

Assistant Professor, Harvard Medical School & Director of the Grousbeck Gene Therapy Center, Schepens Eye and Ear Institute, Massachusetts Eye and Ear Infirmary, Boston MA, USA 

Luk H. Vandenberghe, PhD is Assistant Professor at Harvard Medical School and Director of the Grousbeck Gene Therapy Center at the Massahusetts Eye and Ear Infirmary in Boston, Massachusetts in the United States. Dr. Vandenberghe was trained as a biochemical engineer at the University of Leuven in Belgium and pursued a PhD in Biomedical Sciences with a focus on virology and viral gene therapy. His laboratory is interested in questions on the host-vector biology of human gene transfer, the development of enabling technologies to broaden gene therapy applications, and translation of preclinical programs for indications with unmet need. Dr. Vandenberghe is a co-author on over 50 peer reviewed publication including in Nature Medicine, Science and other high impact journals. He holds over a dozen patents related to gene therapy technology which are licensed to multiple biopharmaceutical entities including Biogen, Pfizer, Lonza, Avexis and Voyager Therapeutics.

Dr Dirk Grimm

Group Leader, BioQuant, Heidelberg University Hospital, Germany

Dirk Grimm, PhD is Full Professor for Viral Vector Technologies at Heidelberg University Hospital. He was trained as a biologist at the Universities of Kaiserslautern and Heidelberg (Germany) and pursued a PhD in Biology with a focus on Adeno-associated viral (AAV) vector technology. His laboratory is interested in engineering novel capsid and genome variants of AAV that are specifically optimized for tissue-specific expression of elements for therapeutic gene regulation and genome editing. Dr. Grimm is a co-author on over 70 peer-reviewed publications including in Nature, Nature Structural and Molecular Biology, Journal of Clinical Investigation, Blood and other high-impact journals.

SPEAKERS

Luk Vandenberghe
Assistant Professor, Ophthalmology, Director, Grousbeck Gene Therapy Center, Massachusetts Eye & Ear Infirmary at Harvard Medical School
Dirk Grimm
Professor for viral vector technologies at Aesthetic and Preventive Medicine at Heidelberg University HospitalÐETHIANUM

You might also like

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
13
Hrs
26
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
27
Days
5
Hrs
26
Min
Register

Taking a right first-time approach to optimize end-to-end viral vector...

H Lesch
J Depollier
Hanna Lesch
Hanna Lesch
Chief Technology Officer at Exothera
Julien Depollier
Julien Depollier
Business Director, Americas at Polyplus-transfection
9 Jun 2022
22
Days
5
Hrs
26
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
20
Days
5
Hrs
26
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
13
Days
13
Hrs
26
Min
Register